Shopping Cart
- Remove All
Your shopping cart is currently empty
ERG245 is a BCAT1 inhibitor that promotes oxidative phosphorylation (OXPHOS) in CD8+ T cells by selectively inhibiting the enzymatic activity of BCAT1, thereby increasing the cytotoxic capacity of CD8+ T cells. ERG245, when administered in combination with the anti-PD-1 antibody Pembrolizumab, induces tumor regression in preclinical settings, and it can be used as a research agent within the field of immuno-oncology.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 10 mg | Inquiry | Backorder | |
| 50 mg | Inquiry | Backorder |
| Description | ERG245 is a BCAT1 inhibitor that promotes oxidative phosphorylation (OXPHOS) in CD8+ T cells by selectively inhibiting the enzymatic activity of BCAT1, thereby increasing the cytotoxic capacity of CD8+ T cells. ERG245, when administered in combination with the anti-PD-1 antibody Pembrolizumab, induces tumor regression in preclinical settings, and it can be used as a research agent within the field of immuno-oncology. |
| Synonyms | ERG-245 |
| Molecular Weight | 347.2 |
| Formula | C17H15BrO3 |
| Smiles | BrC1=CC=C(C(C(C2=CC=CC=C2)CCC(O)=O)=O)C=C1 |
| Color | White |
| Appearance | Solid |
| Storage | store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.